The aim of this study was to evaluate the concentrations of VEGF and CA 15-3 in the plasma of patients with early-stage BC and in control groups, which consisted of a group of patients with benign breast lesions (fibroadenoma) and a group of healthy individuals. The gene discussed is VEGFA; the disease is Fibroadenoma.